CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 54 of the 58 references it cites were found in a registry or an index.
Abstract
Introduction CDKN2A (p16) inactivation is common in lung cancer and occurs via homozygous deletions, methylation of promoter region, or point mutations. Although p16 promoter methylation has been linked to KRAS mutation and smoking, the associations between p16 inactivation mechanisms and other common genetic mutations and smoking status are still controversial or unknown.Methods We determined all three p16 inactivation mechanisms with the use of multiple methodologies for genomic status, methylation, RNA, and protein expression, and correlated them with EGFR, KRAS, STK11 mutations and smoking status in 40 cell lines and 45 tumor samples of primary non-small-cell lung carcinoma. We also performed meta-analyses to investigate the impact of smoke exposure on p16 inactivation.Results p16 inactivation was the major mechanism of RB pathway perturbation in non-small-cell lung carcinoma, with homozygous deletion being the most frequent method, followed by methylation and the rarer point mutations. Inactivating mechanisms were tightly correlated with loss of mRNA and protein expression. p16 inactivation occurred at comparable frequencies regardless of mutational status of EGFR, KRAS, and STK11, however, the major inactivation mechanism of p16 varied. p16 methylation was linked to KRAS mutation but was mutually exclusive with EGFR mutation. Cell lines and tumor samples demonstrated similar results. Our meta-analyses confirmed a modest positive association between p16 promoter methylation and smoking.Conclusion Our results confirm that all the inactivation mechanisms are truly associated with loss of gene product and identify specific associations between p16 inactivation mechanisms and other genetic changes and smoking status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“KRAS mutations are also correlated with the epigenetic silencing of CDKN2A by promoter hypermethylation [124].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“The random-effects model was used for heterogeneous studies whereas the fixed-effects model was applied if the studies were homogeneous.(30) To prevent one of the studies from dominating the results by contributing a larger number of samples or a big effect size, we adopted the leave-one-out strategy by removing data…”
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Primary, Secondary, and Meta-Analysis of Research
GLASS, G. V. (1976) · Educational Researcher · doi:10.3102/0013189x005010003 · Cited by 4,890
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 2×
“None of the EGFR-mutated cases demonstrated p16 promoter methylation, which has been identified as a common mechanism of p16 inactivation in lung adenocarcinomas in this as well as in a number of other studies.(9,12,25) Our analysis revealed that EGFR mutations and p16 methylation were mutually exclusive in all cases,…”
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 1×
“Several new potential targets for therapeutic approaches have also been identified recently.(15,16) A study of these mutations may eventually lead to novel therapeutic applications.”
Lung cancer in never smokers — a different disease
Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2190 · Cited by 1,608 · cited 2×
“However, approximately 25% of lung cancer cases worldwide and about 15% of the cases in the United States are not attributable to smoking.(5,6) The most common type of lung cancer among never smokers is adenocarcinoma, and it is found to be more prevalent among East Asians and women.”
Self-citationLKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064 · cited 1×
“More recently, STK11 has been identified as being frequently mutated in lung adenocarcinoma and could play an important role in lung cancer differentiation and metastasis.(11,50) However, the relationship between STK11 mutation and p16 inactivation has never been investigated.”
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993
Lung cancer in never smokers – A review
Couraud, S., Zalcman, G., Milleron, B., Morin, F., & Souquet, P.-J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.007 · Cited by 960 · cited 1×
“However, approximately 25% of lung cancer cases worldwide and about 15% of the cases in the United States are not attributable to smoking.(5,6) The most common type of lung cancer among never smokers is adenocarcinoma, and it is found to be more prevalent among East Asians and women.”
Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all
Gil, J., & Peters, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1987 · Cited by 843 · cited 3×
“The collection of whole cell extracts was performed as described in a previous study.26 Protein digestion and identification by liquid chromatography-MS/MS were performed as described previously.26 Three International Protein Indexes (IPIs) were identified for CDKN2A in which 1381Copyright © 2013 by the International…”
InfluentialInactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sánchez‐Céspedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J. M., Westra, W. H., Herman, J. G., & Sidransky, D. (2002) · PubMed · Cited by 698
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
Shigematsu, H., & Gazdar, A. F. (2006) · International Journal of Cancer · doi:10.1002/ijc.21496 · Cited by 657 · cited 1×
“As previously reported, EGFR and KRAS mutations were mutually exclusive.(28) Mutations of EGFR and STK11 were also found to be mutually exclusive in the 40 cell lines.”
Self-citationLung Cancer in Never Smokers: A Review
Subramanian, J., & Govindan, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8015 · Cited by 655
Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer‐Müller, S., Fong, K. M., Virmani, A. K., Geradts, J., Gazdar, A. F., & Minna, J. D. (2001) · PubMed · Cited by 608
Self-citationAn Introduction to Meta–Analysis
Konstantopoulos, S. (2008) · Best Practices in Quantitative Methods · doi:10.4135/9781412995627.d15 · Cited by 432
Kim, D. H., Nelson, H. H., Wiencke, J. K., Zheng, S., Christiani, D. C., Wain, J. C., Mark, E. J., & Kelsey, K. T. (2001) · PubMed · Cited by 365
Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
Ladanyi, M., & Pao, W. (2008) · Modern Pathology · doi:10.1038/modpathol.3801018 · Cited by 364 · cited 1×
“We believe lung cancer prognosis can be improved by a combination of early detection(7) with advances in biology and the subsequent implementation of effective targeted therapies such as those directed against EGFR mutations and ALK translocations.(8,9) Studies have shown that patients with lung adenocarcinoma often h…”
NCI-navy medical oncology branch cell line data base
Phelps, R. M., Johnson, B. E., Ihde, D. C., Gazdar, A. F., Carbone, D. P., McClintock, P. R., Linnoila, R. I., Matthews, M. J., Bunn, P. A., Carney, D., et al. (1996) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240630505 · Cited by 303
Self-citationToyooka, S., Maruyama, R., Toyooka, K. O., McLerran, D., Feng, Z., Fukuyama, Y., Virmani, A. K., Zochbauer‐Muller, S., Tsukuda, K., Sugio, K., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10787 · Cited by 288
Self-citationThe p16INK4a-RB pathway : molecular link between cellular senescence and tumor suppression
Ohtani, N., Yamakoshi, K., Takahashi, A., & Hara, E. (2004) · The Journal of Medical Investigation · doi:10.2152/jmi.51.146 · Cited by 276 · cited 1×
“p16 is a tumor suppressor, functions as an inhibitor of CDK4 and CDK6, the D-type cyclin-dependent kinases that initiate the phosphorylation of the retinoblastoma tumor suppressor protein RB, and induces cell-cycle arrest.(18) Both alleles must be inactivated before its function is eliminated.”
Vaissière, T., Hung, R. J., Zaridze, D., Moukeria, A., Cuenin, C., Fasolo, V., Ferro, G., Paliwal, A., Hainaut, P., Brennan, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2489 · Cited by 258 · cited 1×
“A number of studies reported that p16 promoter methylation was significantly associated with smoking but this finding was not reproduced by others.(21,31) The effect of smoke exposure on p16 inactivation can be clarified by performing a meta-analysis.”
Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D. S., Tang, X., MacAulay, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007464 · Cited by 228
Self-citationGandhi, J., Zhang, J., Xie, Y., Soh, J., Shigematsu, H., Zhang, W., Yamamoto, H., Peyton, M., Girard, L., Lockwood, W. W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004576 · Cited by 198
Self-citationToyooka, S., Tokumo, M., Shigematsu, H., Matsuo, K., Asano, H., Tomii, K., Ichihara, S., Suzuki, M., Aoe, M., Date, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2625 · Cited by 163
Self-citationLiu, Y., Lan, Q., Siegfried, J. M., Luketich, J. D., & Keohavong, P. (2006) · Neoplasia · doi:10.1593/neo.05586 · Cited by 140
Promoter hypermethylation of tumor suppressor and tumor‐related genes in non‐small cell lung cancers
Yanagawa, N., Tamura, G., Oizumi, H., Takahashi, N., Shimazaki, Y., & Motoyama, T. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01487.x · Cited by 136
Sánchez‐Céspedes, M., Reed, A. L., Buta, M. R., Li, W., Westra, W. H., Herman, J. G., Yang, S. C., Jen, J., & Sidransky, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203003 · Cited by 130
Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer
Jarmalaitė, S., Kannio, A., Anttila, S. L., Lazutka, J. R., & Husgafvel‐Pursiainen, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11322 · Cited by 100
Jung, H. S., Park, D. K., Kim, M. J., Yu, S. K., Kwon, K. A., Ku, Y. S., Kim, Y. K., & Kim, J. H. (2009) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2009.24.1.43 · Cited by 96
Js, K. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh217 · Cited by 94
Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers
Divine, K. K., Pulling, L. C., Marron‐Terada, P. G., Liechty, K. C., Kang, T., Schwartz, A. G., Bocklage, T. J., Coons, T. A., Gilliland, F. D., & Belinsky, S. A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20761 · Cited by 94
Application of a methylation gene panel by quantitative PCR for lung cancers
Shivapurkar, N., Stastny, V., Suzuki, M., Wistuba, I. I., Li, L., Zheng, Y., Feng, Z., Hol, B. E. A., Prinsen, C., Thunnissen, E., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.03.020 · Cited by 90 · cited 3×
“All other materials and methods for MSP were as described in prior studies.(21,25) The methylation status of p16 in cell lines was confirmed using the Infinium HumanMethylation 450K BeadChip by Illumina (San Diego, CA).”
Self-citationBorczuk, A., Kim, H. K., Yegen, H. A., Friedman, R. A., & Powell, C. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-615oc · Cited by 82 · cited 3×
“2013;8: 1378–1388) Lung cancer is the second most common type of cancer and the leading cause of cancer-related deaths in both men and women in the United States.”
Tessema, M., Yu, Y. Y., Stidley, C. A., Machida, E. O., Schuebel, K. E., Baylin, S. B., & Belinsky, S. A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp114 · Cited by 72
EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
Jang, T. W., Oak, C. H., Chang, H. K., Suo, S. J., & Jung, M. H. (2009) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2009.24.1.48 · Cited by 71
Dose effect of smoking on aberrant methylation in non‐small cell lung cancers
Toyooka, S., Suzuki, M., Tsuda, T., Toyooka, K. O., Maruyama, R., Tsukuda, K., Fukuyama, Y., Iizasa, T., Fujisawa, T., Shimizu, N., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20125 · Cited by 70 · cited 1×
“Studies demonstrated that the frequency of p16 methylation is significantly higher in lung adenocarcinoma with KRAS mutation, however, the associations between p16 inactivation mechanisms and other common genetic mutations in lung adenocarcinoma such as EGFR and STK11 remain controversial or have never been explored.(…”
Self-citationAberrant DNA methylation profiles of non-small cell lung cancers in a Korean population
Kim, D. S., Ick, S., Lee, J., Lee, Y., Choi, J. E., Kim, M., Lim, J., Lee, E. B., Kim, C., Park, T. I., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.04.008 · Cited by 55
Seike, M., Gemma, A., Hosoya, Y., Hemmi, S., Taniguchi, Y., Fukuda, Y., Yamanaka, N., & Kudoh, S. (2000) · PubMed · Cited by 52
Georgiou, E., Valeri, R., Tzimagiorgis, G., Anzel, J., Krikelis, D., Tsilikas, C., Sarikos, G., Destouni, C., Dimitriadou, A., & Kouidou, S. (2007) · European Journal of Cancer Prevention · doi:10.1097/01.cej.0000236260.26265.d6 · Cited by 49
Furonaka, O., Takeshima, Y., Awaya, H., Ishida, H., Kohno, N., & Inai, K. (2004) · Pathology International · doi:10.1111/j.1440-1827.2004.01663.x · Cited by 45
Wu, M., Cheng, Y., Lai, J., Hsu, M., Chen, J., Liu, W., Chiou, M., Chen, C., & Lee, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.20597 · Cited by 43
Miyajima (1994) · Oncology Reports · doi:10.3892/or_00000121 · Cited by 42
Yanagawa, N., Tamura, G., Oizumi, H., Endoh, M., Sadahiro, M., & Motoyama, T. (2011) · PubMed · Cited by 39
Zhang, B., Zhu, W., Yang, P., Liu, T., Jiang, M. H., He, Z., Zhang, S., Chen, W., & Chen, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028882 · Cited by 36 · cited 3×
“A recent study from China reported that smoking is positively correlated with p16 hypermethylation in NSCLC.51 However, the meta-analysis in that study was limited to promoter methylation, which is not the most frequent mechanism of inactivation for p16.”
Homozygous deletion of p16INK4aand tobacco carcinogen exposure in nonsmall cell lung cancer
Kraunz, K. S., Nelson, H. H., Lemos, M., Godleski, J. J., Wiencke, J. K., & Kelsey, K. T. (2006) · International Journal of Cancer · doi:10.1002/ijc.21522 · Cited by 35 · cited 3×
“A recent study from China reported that smoking is positively correlated with p16 hypermethylation in NSCLC.51 However, the meta-analysis in that study was limited to promoter methylation, which is not the most frequent mechanism of inactivation for p16.”
Innovative Proteomic Approaches for Cancer Biomarker Discovery
Faça, V. M., Krasnoselsky, A. L., & Hanash, S. (2007) · BioTechniques · doi:10.2144/000112541 · Cited by 35 · cited 2×
“Protein digestion and identification by liquid chromatography-MS/MS were performed as described previously.(26) Three International Protein Indexes (IPIs) were identified for CDKN2A in which”
Self-citationIwakawa, R., Kohno, T., Anami, Y., Noguchi, M., Suzuki, K., Matsuno, Y., Mishima, K., Nishikawa, R., Tashiro, F., & Yokota, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4552 · Cited by 32 · cited 4×
“A recent study from China reported that smoking is positively correlated with p16 hypermethylation in NSCLC.51 However, the meta-analysis in that study was limited to promoter methylation, which is not the most frequent mechanism of inactivation for p16.”
InfluentialHypermethylation of p16INK4a in Korean Non-small Cell Lung Cancer Patients
Hong, Y., Roh, M.-S., Kim, N.-Y., Lee, H., Kim, H.-K., Lee, K.-E., Kwak, J., & Kim, J.-Y. (2007) · Journal of Korean Medical Science · doi:10.3346/jkms.2007.22.s.s32 · Cited by 18
[Histological Typing of Lung and Pleural Tumors (3rd edition, 1999): Malignant epithelial tumors].
Shimosato, Y. (2002) · PubMed · Cited by 11
Cited by
Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer
Zhao, R., Choi, B. Y., Lee, M.-H., Bode, A. M., & Dong, Z. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.017 · Cited by 425
“However, changes in STK11 (also known as LKB1), a gene frequentlymutated in lung adenocarcinomas, have no impact on CDKN2A inactivationmechanisms (Tam et al., 2013).”
BackgroundInfluentialLung cancer epigenetics: From knowledge to applications
Duruisseaux, M., & Esteller, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.005 · Cited by 283
Molecular and epigenetic mechanisms of Cr(VI)-induced carcinogenesis
Chen, Q. Y., Murphy, A., Sun, H., & Costa, M. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114636 · Cited by 174
Self-citationCells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Oser, M. G., Fonseca, R., Chakraborty, A. A., Brough, R., Spektor, A., Jennings, R. B., Flaifel, A., Novak, J. S., Gulati, A., Buss, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0389 · Cited by 173
An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
Girard, L., Rodriguez-Canales, J., Behrens, C., Thompson, D. M., Botros, I. W., Tang, H., Xie, Y., Rekhtman, N., Travis, W. D., Wistuba, I. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2900 · Cited by 154
“RNA was prepared with TRIzol (Invitrogen) as previously described from ADCs resected in British Columbia, Canada and collected by Dr. Stephen Lam (British Columbia Cancer Agency, Vancouver, BC, Canada) (16, 17).”
Self-citation
Metadata
- Authors
- Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., Selamat, S. A., Laird-Offringa, I. A., Taguchi, A., Hanash, S., Shames, D., Ma, X., Zhang, M. Q., Lam, W. L., & Gazdar, A.
- Affiliations
- BC Cancer Agency (CA)
- The University of Texas Southwestern Medical Center (US)
- The University of Texas at Dallas (US)
- Texas Scottish Rite Hospital for Children (US)
- University of Southern California (US)
- Fred Hutch Cancer Center (US)
- Genentech (US)
- Corresponding author
- Gazdar, Adi
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 8
- Issue
- 11
- Pages
- 1378-1388
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC3951422
- OpenAlex
- W1971623971
- Cited by
- 109
- References
- 58
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 11 · 2023: 13 · 2022: 5 · 2021: 18 · 2020: 8 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 1 · 2014: 5
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 761 d)
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Canary Foundation
- University of Texas Southwestern Medical Center (P50CA70907)
- National Institutes of Health
- National Human Genome Research Institute (R01HG001696, HG001696)
- National Cancer Institute ((P50-CA70907, P50CA070907, U01CA086402)
- National Institute of Environmental Health Sciences (U01ES017166)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- CDKN2A, p16, non-small cell lung cancer, p16 promoter methylation, homozygous deletion, smoking, KRAS mutation, EGFR mutation, STK11 mutation, Rb pathway, tumor suppressor inactivation, gene expression loss
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Prognosis, Proto-Oncogene Proteins, Smoking, Tumor Cells, Cultured, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Carcinoma, Adenosquamous, Carcinoma, Large Cell, ras Proteins, DNA Methylation, Cyclin-Dependent Kinase Inhibitor p16, DNA Copy Number Variations, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.